0JQ2.LKALA BIO, Inc.

À propos

Kala Bio, Inc. operates as a biopharmaceutical enterprise focused on developing and bringing to market innovative treatments. The company employs its unique, proprietary nanoparticle technology, designed to effectively penetrate mucus barriers. Initially, its efforts are concentrated on addressing various ocular conditions. Established in 2009 by founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, the firm maintains its headquarters in Arlington, Massachusetts.

www.kalarx.com

Statistiques clés

Capitalisation

254.16K

BPA

-165.50

Rendement dividende

0.00%

Bêta

-2.41

P/B

0.64

ROE

-385.6%

Secteur

Healthcare

Industrie

Biotechnology

PDG

Avi Minkowitz

Employés

38

Date IPO

2018-01-29

Pays

US